RT Journal Article SR Electronic T1 Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP jnmt.122.264928 DO 10.2967/jnmt.122.264928 A1 Jadvar, Hossein A1 Colletti, Patick M. YR 2023 UL http://tech.snmjournals.org/content/early/2023/01/04/jnmt.122.264928.abstract AB Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA-11, 18F-DCFPyL) and radiopharmaceutical therapy (177Lu-PSMA-617) have paved the way for theranostics as a viable care strategy for men with metastatic castration-resistant prostate cancer. The imaging clinical trials OSPREY, CONDOR and those conducted at the University of California (Los Angeles and San Francisco) as well as the randomized phase 3 therapy trial VISION have been the fruitful beginnings for PSMA theranostics. There are currently several ongoing clinical trials to expand the reach of PSMA theranostics to the earlier phases of prostate cancer and to optimize its utility in combination therapeutic regimens. We provide a brief narrative review of the many PSMA-directed radiopharnaecutical therapy clinical trials with the beta emitter, 177Lu-PSMA-617, and the alpha emitter, 225Ac-PSMA-617, in prostate cancer.